bluebird bio Management

Management criteria checks 2/4

bluebird bio's CEO is Andrew Obenshain, appointed in Jan 2021, has a tenure of 3.83 years. total yearly compensation is $3.05M, comprised of 22.4% salary and 77.6% bonuses, including company stock and options. directly owns 0.048% of the company’s shares, worth €33.14K. The average tenure of the management team and the board of directors is 2.3 years and 13.7 years respectively.

Key information

Andrew Obenshain

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage	22.4%
CEO tenure	3.8yrs
CEO ownership	0.05%
Management average tenure	2.3yrs
Board average tenure	13.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Andrew Obenshain's remuneration changed compared to bluebird bio's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$293m
Jun 30 2024	n/a	n/a	-US$319m
Mar 31 2024	n/a	n/a	-US$301m
Dec 31 2023	US$3m	US$682k	-US$212m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$89m
Dec 31 2022	US$2m	US$643k	-US$230m
Sep 30 2022	n/a	n/a	-US$431m
Jun 30 2022	n/a	n/a	-US$507m
Mar 31 2022	n/a	n/a	-US$563m
Dec 31 2021	US$9m	US$486k	-US$563m

Compensation vs Market: Andrew's total compensation ($USD3.05M) is above average for companies of similar size in the German market ($USD472.15K).

Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.

CEO

Andrew Obenshain (50 yo)

3.8yrs

Tenure

US$3,049,181

Compensation

Mr. Andrew Obenshain has been the Chief Executive Officer and Director of bluebird bio, Inc. since 2021 and serves as its President. He served as President of Severe Genetic Diseases since October 2020 unt...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Andrew Obenshain	President	3.8yrs	US$3.05m	0.048% € 33.1k
Thomas Klima	Chief Commercial Officer & COO	2.3yrs	US$1.33m	0.087% € 60.0k
Richard Colvin	Chief Medical Officer	3.7yrs	US$1.34m	0.022% € 15.3k
Oliver Sterling	CFO & Principal Accounting Officer	less than a year	no data	no data
Joseph Vittiglio	Chief Legal & Business Officer and Secretary	1.8yrs	no data	0.0037% € 2.6k
Jess Rowlands	Head of Corporate Communications	1.9yrs	no data	no data
Andrea Walton	Chief People Officer	2.8yrs	no data	no data
Kasra Kasraian	Senior Vice President of Technical Development & Operations	no data	no data	no data
Scott Shoemaker	Senior Vice President of Quality	3.8yrs	no data	no data
Sarah Alspach	Senior Vice President of External Affairs	1.9yrs	no data	no data
Leslie Wilder	VP & Head of Regulatory Science	no data	no data	no data
Jessica Whitten	VP & Global Controller	no data	no data	no data

2.3yrs

Average Tenure

52yo

Average Age

Experienced Management: BLE's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Andrew Obenshain	President	3.8yrs	US$3.05m	0.048% € 33.1k
Philip Reilly	Member of Scientific Advisory Board	13.7yrs	no data	no data
Philippe Leboulch	Co-Chair of Scientific Advisory Board	no data	no data	no data
Stephen Goff	Member of Scientific Advisory Board	13.7yrs	no data	no data
Mark Vachon	Independent Chairman	10.3yrs	US$200.91k	0.013% € 8.8k
Mitchell Finer	Member of Scientific Advisory Board	9.3yrs	US$1.57m	no data
Malcolm Brenner	Member of Scientific Advisory Board	13.7yrs	no data	no data
Christof von Kalle	Member of Scientific Advisory Board	13.7yrs	no data	no data
John Agwunobi	Independent Director	7.4yrs	US$160.91k	0.014% € 9.3k
Nick Leschly	Director	14.7yrs	US$96.41k	0.23% € 160.7k
R. Humphries	Member of Scientific Advisory Board	13.7yrs	no data	no data
Elisabeth Leiderman	Independent Director	3yrs	US$167.91k	0.011% € 7.9k

13.7yrs

Average Tenure

65yo

Average Age

Experienced Board: BLE's board of directors are seasoned and experienced ( 13.7 years average tenure).

bluebird bio Management

Management criteria checks 2/4

Key information

Recent management updates

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

President recently sold €54k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New major risk - Negative shareholders equity

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Revenue and earnings growth

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Now 41% undervalued after recent price drop

Bluebird Bio, Inc. Announces FDA Approval of LYFGENIA™? (Lovo-Ccel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

Now 24% undervalued

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.94 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Insider selling

President recently sold €54k worth of stock

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$1.36 loss in 2Q 2022)

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

First quarter 2023 earnings released: EPS: US$0.21 (vs US$1.66 loss in 1Q 2022)

Less than half of directors are independent

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.94 loss per share (vs US$2.23 loss in 3Q 2021)

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold €78k worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold €94k worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer

CEO & Director recently sold €65k worth of stock

bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022

bluebird bio, Inc. Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program

bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor

bluebird bio, Inc. Announces Updated Results from its Phase 1/2 HGB-206 Study of Lovotibeglogene Autotemcel Gene Therapy

New Data At ASH21, Published in Nejm Further Demonstrate Beti-Cel as A Potentially Curative One-Time Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Ti and Normal or Near-Normal Adult Hb Levels

Bluebird Bio, Inc. Announces FDA Priority Review of Biologics License Application for Beti-Cel Gene Therapy for Patients with ß-Thalassemia Who Require Regular Red Blood Cell Transfusions

Third quarter 2021 earnings released: US$3.16 loss per share (vs US$2.94 loss in 3Q 2020)

Insufficient new directors